Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic
breast cancer are eligible to a randomized trial. Patients receiving standard first line
therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to
also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Breast Cancer Diagnosis, Breast Cancer, breast carcinoma, cancer, breast
Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions),
Letrozole 2.5Mg Tab
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.